The relationship between amyloid structure and cytotoxicity

Subcellular Localization of Disease-Associated Prion Protein in the Human Brain

Prions are infectious proteins, mostly having a self-propagating amyloid (filamentous protein polymer) structure consisting of an abnormal form of a normally soluble protein. These prions arise spontaneously in the cell without known reason, and their effects were generally considered to be fatal based on prion diseases in humans or mammals. However, the wide array of prion studies in yeast including filamentous fungi revealed that their effects can range widely, from lethal to very mild (even cryptic) or functional, depending on the nature of the prion protein and the specific prion variant (or strain) made by the same prion protein but with a different conformation. This prion biology is affected by an array of molecular chaperone systems, such as Hsp40, Hsp70, Hsp104, and combinations of them. In parallel with the systems required for prion propagation, yeast has multiple anti-prion systems, constantly working in the normal cell without overproduction of or a deficiency in any protein, which have negative effects on prions by blocking their formation, curing many prions after they arise, preventing prion infections, and reducing the cytotoxicity produced by prions. From the protectors of nascent polypeptides (Ssb1/2p, Zuo1p, and Ssz1p) to the protein sequesterase (Btn2p), the disaggregator (Hsp104), and the mysterious Cur1p, normal levels of each can cure the prion variants arising in its absence. The controllers of mRNA quality, nonsense-mediated mRNA decay proteins (Upf1, 2, 3), can cure newly formed prion variants by association with a prion-forming protein. The regulator of the inositol pyrophosphate metabolic pathway (Siw14p) cures certain prion variants by lowering the levels of certain organic compounds. Some of these proteins have other cellular functions (e.g., Btn2), while others produce an anti-prion effect through their primary role in the normal cell (e.g., ribosomal chaperones). Thus, these anti-prion actions are the innate defense strategy against prions. Here, we outline the anti-prion systems in yeast that produce innate immunity to prions by a multi-layered operation targeting each step of prion development.

The molecular lifecycle of amyloid – Mechanism of assembly, mesoscopic organisation, polymorphism, suprastructures, and biological consequences

Misfolding of the natively α-helical prion protein into a β-sheet rich isoform is related to various human diseases such as Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker syndrome. In humans, the disease phenotype is modified by a methionine/valine polymorphism at codon 129 of the prion protein gene. Using a combination of hydrogen/deuterium exchange coupled to NMR spectroscopy, hydroxyl radical probing detected by mass spectrometry, and site-directed mutagenesis, we demonstrate that stop mutants of the human prion protein have a conserved amyloid core. The 129 residue is deeply buried in the amyloid core structure, and its mutation strongly impacts aggregation. Taken together the data support a critical role of the polymorphic residue 129 of the human prion protein in aggregation and disease.

Mutations that cause Huntington's Disease involve a polyglutamine (polyQ) sequence expansion beyond 35 repeats in exon 1 of Huntingtin. Intracellular inclusion bodies of mutant Huntingtin protein are a key feature of Huntington's disease brain pathology. We previously showed that in cell culture the formation of inclusions involved the assembly of disordered structures of mHtt exon 1 fragments (Httex1) and they were enriched with translational machinery when first formed. We hypothesized that nascent mutant Httex1 chains co-aggregate during translation by phase separation into liquid-like disordered aggregates and then convert to more rigid, amyloid structures. Here we further examined the mechanisms of inclusion assembly in a human epithelial kidney (AD293) cell culture model. We found mHttex1 did not appear to stall translation of its own nascent chain, or at best was marginal. We also found the inclusions appeared to recruit low levels of RNA but there was no difference in enrichment between early formed and mature inclusions. Proteins involved in translation or ribosome quality control were co-recruited to the inclusions (Ltn1 Rack1) compared to a protein not anticipated to be involved (NACAD), but there was no major specificity of enrichment in the early formed inclusions compared to mature inclusions. Furthermore, we observed co-aggregation with other proteins previously identified in inclusions, including Upf1 and chaperone-like proteins Sgta and Hspb1, which also suppressed aggregation at high co-expression levels. The newly formed inclusions also contained immobile mHttex1 molecules which points to the disordered aggregates being mechanically rigid prior to amyloid formation. Collectively our findings show little evidence that inclusion assembly arises by a discrete clustering of stalled nascent chains and associated quality control machinery. Instead, the machinery appear to be recruited continuously, or secondarily, to the nucleation of inclusion formation.

Many human neurodegenerative diseases are associated with amyloid fibril formation. Inhibition of amyloid formation is of importance for therapeutics of the related diseases. However, the development of selective potent amyloid inhibitors remains challenging. Here based on the structures of amyloid β (Aβ) fibrils and their amyloid-forming segments, we designed a series of peptide inhibitors using RosettaDesign. We further utilized a chemical scaffold to constrain the designed peptides into β-strand conformation, which significantly improves the potency of the inhibitors against Aβ aggregation and toxicity. Furthermore, we show that by targeting different Aβ segments, the designed peptide inhibitors can selectively recognize different species of Aβ. Our study developed an approach that combines the structure-based rational design with chemical modification for the development of amyloid inhibitors, which could be applied to the development of therapeutics for different amyloid-related diseases.

The acute phase response is characterized by changes in the serum concentrations of many proteins. A 1000-fold increase in the concentration of serum amyloid A (SAA) protein occurs within 24 hours of LPS injection in the mouse. We have isolated a cDNA clone and its corresponding genomic phage for a third, previously unreported SAA protein. The sequence of the cDNA, the gene's exons and neighboring DNA are presented along with the mapping evidence supporting the gene structure.

Until recently, studies of amyloids were aimed exclusively at revealing their role in the occurrence of dangerous diseases in humans and animals. However, they are widely distributed in nature and are involved in the regulation of essential vital processes in representatives of all three domains of the living world: archaea, bacteria and eukaryotes. The question of the biological significance of the prions – a special class of amyloids, isstill under discussion. The discovery of new functional amyloids became possible due to the development of the bioinformatic and proteomic methods for identification of amyloid-forming proteins. The review describes the way from the study of pathological amyloid structures to the investigation of adaptive amyloids inbacteria, plants, and animals. The importance of the amyloid structure, based on the principle of conformation template copying, as one of the most important forms of supramolecular organization of proteins isshown.

Prion diseases are transmissible, progressive and invariably fatal neurodegenerative conditions associated with misfolding and aggregation of a host-encoded cellular prion protein, PrPC. They have occurred in a wide range of mammalian species including human. Human prion diseases can arise sporadically, be hereditary or be acquired. Sporadic human prion diseases include Cruetzfeldt-Jacob disease (CJD), fatal insomnia and variably protease-sensitive prionopathy. Genetic or familial prion diseases are caused by autosomal dominantly inherited mutations in the gene encoding for PrPC and include familial or genetic CJD, fatal familial insomnia and Gerstmann-Sträussler-Scheinker syndrome. Acquired human prion diseases account for only 5% of cases of human prion disease. They include kuru, iatrogenic CJD and a new variant form of CJD that was transmitted to humans from affected cattle via meat consumption especially brain. This review presents information on the epidemiology, etiology, clinical assessment, neuropathology and public health concerns of human prion diseases. The role of the PrP encoding gene (PRNP) in conferring susceptibility to human prion diseases is also discussed.

Designed inhibitors to reduce amyloid virulence and cytotoxicity and combat neurodegenerative and infectious diseases

Chapter 25 - The zoonotic potential of animal prion diseases

Lead(II) ions adsorption onto amyloid particulates: An in depth study

The self-assembly of proteins is an essential process for a variety of cellular functions including cell respiration, mobility and division. On the other hand, protein or peptide misfolding and aggregation is related to the development of Parkinson’s disease and Alzheimer’s disease, among other aggregopathies. As a consequence, significant research efforts are directed towards the understanding of this process. In this review, we are focused on the use of UV-Visible Absorption Spectroscopy, Fluorescence Spectroscopy and Circular Dichroism to evaluate the self-organization of proteins and peptides in solution. These spectroscopic techniques are commonly available in most chemistry and biochemistry research laboratories, and together they are a powerful approach for initial as well as routine evaluation of protein and peptide self-assembly and aggregation under different environmental stimulus. Furthermore, these spectroscopic techniques are even suitable for studying complex systems like those in the food industry or pharmaceutical formulations, providing an overall idea of the folding, self-assembly, and aggregation processes, which is challenging to obtain with high-resolution methods. Here, we compiled and discussed selected examples, together with our results and those that helped us better to understand the process of protein and peptide aggregation. We put particular emphasis on the basic description of the methods as well as on the experimental considerations needed to obtain meaningful information, to help those who are just getting into this exciting area of research. Moreover, this review is particularly useful to those out of the field who would like to improve reproducibility in their cellular and biomedical experiments, especially while working with peptide and protein systems as an external stimulus. Our final aim is to show the power of these low-resolution techniques to improve our understanding of the self-assembly of peptides and proteins and translate this fundamental knowledge in biomedical research or food applications.

Huntington's disease is neurodegenerative disease caused by an expanded polyglutamine-coding CAG repeat in exon 1 of the huntingtin gene. Huntingtin exon 1 forms the primary toxic amyloid structure in Huntington's disease; disease severity is directly correlated with polyglutamine length. Recent works have shown that fully formed amyloid plaques may not represent the most toxic species in Huntington's disease; the most neurotoxic species may be small, diffuse oligomer (4 - 20 monomer units) that are precursors to amyloid plaques. While the polyglutamine region is undisputed as the primary constituent of amyloid structure, aggregation kinetics and morphology are regulated by the presence of flanking sequences that are N- and C-terminal to theamyloid forming tract. The first seventeen residues of huntingtin exon 1 (Nt17) can form an amphipathic &agr;-helix depending upon solution conditions and the presence of a binding partner, and in most cases, mediates oligomer formation. C-terminal to the polyglutamine tract is a proline-rich region, or in the case of a model peptide a polyproline region (polyP), that can form a polyproline-type II (PPII) helix, which may regulate Nt17 in huntingtin protein with short polyglutamine regions. Much is unknown regarding residue-specific Nt17-Nt17 and Nt17-polyP interactions. The work described here utilized state-of-the-art deuterium exchange mass spectrometry techniques to identify critical hydrophilic residues in early stages of oligomer formation. Monomeric and multimeric conformations of Nt17, idependent og the polyglutamine domain, were then studied using ion mobility-mass spectrometry and molecular dynamics to gain insight into the earliest stages of Nt17-Nt17 association, and thus, aggregation. Monomeric and multimeric Nt17 could form extended helices in the gas phase. Key hydrophilic residues were chemically modified, which resulted in a sharp decline in multimer formation. Finally, Nt17-polyP interactions were probed using gas-phase deuterium exchange mass spectrometry, supplemented with molecular dynamics and an exchange kinetics model. The obtained gas-phase structures showed a reduction in Nt17 extended &agr;-helix, when compared to a monomeric and extended homodimeric conformation. Thus, it is hypothesized that polyP regulates Nt17 by not allowing transition to the amphipathic &agr;-helix. The results of this study examine the structural heterogeneity of a sequence thought to drive a potentially toxic aggregate morphology, pinpoint key residues in early oligomer formation, and provide strategies for regulation of oligomer formation.

Abnormal folding of the cellular prion protein (PrPC) is a key feature in prion diseases. Here we show that two pathogenic mutations linked to inherited prion diseases in humans severely affect folding and maturation of PrPC in the secretory pathway of neuronal cells. PrP-T183A and PrP-F198S adopt a misfolded and partially protease-resistant conformation, lack the glycosylphosphatidylinositol anchor, and are not complex glycosylated. These misfolded PrP mutants are not retained in the endoplasmic reticulum and are not subjected to the endoplasmic reticulum-associated degradation pathway. They rather are secreted, moreover, these mutants can be internalized by heterologous cells. Structural studies indicated that the side chains of Thr183 and Phe198 contribute to interactions between secondary structure elements in the C-terminal globular domain of PrPC. Consequently, we reasoned that a destabilized tertiary structure of these mutants could account for the defect in maturation. Indeed, mutations predicted to interfere selectively with the packing of the hydrophobic core of PrPC prevented the addition of the glycosylphosphatidylinositol anchor. Our study reveals that formation of the C-terminal globular domain of PrPC has an impact on membrane anchoring and indicates that misfolded secreted forms of the prion protein are linked to inherited prion diseases in humans.